---
title: "Nucala (mepolizumab), all indications: Specific populations questions"
description: "Specific populations questions on Nucala (mepolizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Is Nucala cleared by the kidneys (renal impairment)? Does liver impairment affect Nucala? Can you breastfeed while taking Nucala? Is Nucala safe for older adults? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/nucala/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab), all indications: Specific populations questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)  
Indication pages: [Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)

## Specific populations

<a id="nucala-kidney-impairment"></a>

### Is Nucala cleared by the kidneys (renal impairment)?

> “Patients with Renal Impairment: No clinical trials have been conducted to investigate the effect 
> of renal impairment on the pharmacokinetics of mepolizumab. Based on population 
> pharmacokinetic analyses, mepolizumab clearance was comparable between subjects with 
> creatinine clearance values between 50 and 80 mL/min and patients with normal renal function. 
> There are limited data available in subjects with creatinine clearance values <50 mL/min;”

Source: [NUCALA: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=18)

> “however, mepolizumab is not cleared renally.”

Source: [NUCALA: Prescribing information, page 19, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=19)

Note: The two passages are one sentence divided by a page break in the Prescribing Information.

<a id="nucala-liver-impairment"></a>

### Does liver impairment affect Nucala?

> “Patients with Hepatic Impairment: No clinical trials have been conducted to investigate the 
> effect of hepatic impairment on the pharmacokinetics of mepolizumab. Since mepolizumab is 
> degraded by widely distributed proteolytic enzymes, not restricted to hepatic tissue, changes in 
> hepatic function are unlikely to have any effect on the elimination of mepolizumab.”

Source: [NUCALA: Prescribing information, page 19, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=19)

<a id="nucala-older-adults"></a>

### Is Nucala safe for older adults?

> “Of the total number of patients treated with NUCALA (n = 4106) for severe asthma, HES, 
> EGPA, CRSwNP, and COPD, 1073 (26%) were 65 years of age and older and 241 (6%) were 
> 75 years of age and older [see Clinical Studies (14)]. No overall differences in safety and 
> effectiveness were observed between these patients and younger patients. Other reported clinical 
> experience has not identified differences in responses between the elderly and younger patients, 
> but greater sensitivity in some older individuals cannot be ruled out.”

Source: [NUCALA: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=15)

> “Age: Population pharmacokinetics analyses indicated there was no significant effect of age on 
> mepolizumab clearance.”

Source: [NUCALA: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=18)

Note: The first passage pools patients from every approved indication.

## Pregnancy and breastfeeding

<a id="nucala-breastfeeding"></a>

### Can you breastfeed while taking Nucala?

> “There is no information regarding the presence of mepolizumab in human milk, the effects on the 
> breastfed infant, or the effects on milk production. However, mepolizumab is a humanized 
> monoclonal antibody (IgG1 kappa), and immunoglobulin G (IgG) is present in human milk in 
> small amounts. Mepolizumab was present in the milk of cynomolgus monkeys postpartum 
> following dosing during pregnancy [see Use in Specific Populations (8.1)]. The developmental 
> and health benefits of breastfeeding should be considered along with the mother’s clinical need 
> for NUCALA and any potential adverse effects on the breastfed infant from mepolizumab or 
> from the underlying maternal condition.”

Source: [NUCALA: Prescribing information, page 13, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=13)

## Related pages
- [Medical information: Nucala (mepolizumab): All indications](https://www.evicenter.com/medical-information/nucala)
- [Indication](https://www.evicenter.com/medical-information/nucala/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/nucala/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/nucala/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/nucala/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala/access-and-coverage)
